About Us | Contact Us |        

Type 2 Inflammation in Asthma: Considerations for Targeted Therapy

Pulmonary Disease
Curriculum:
Can You Do It Better? -- A Unique Approach to Enabling Improved Asthma Management
Credits:
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
December 20, 2018
Expiration Date:
December 20, 2019

Primary Audience:

Pulmonologists, allergists, primary care and internal medicine physicians, and others who encounter asthma

Relevant Terms:

asthma; uncontrolled asthma; targeted therapy; severe asthma

Emily DiMango, MD

Emily DiMango, MD
Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Director, Adult Cystic Fibrosis Program
Columbia University Medical Center
New York, NY

Dr. DiMango serves as the Principal Investigator for the New York Consortium of the American Lung Association Asthma Research Center and the Columbia site of the NIH-sponsored Asthmanet and PRECISE networks. She has studied the effect of household allergens on the need for pharmacologic therapy in asthma and has published numerous articles in the field of asthma.

Michael E. Wechsler, MD, MMSc

​Michael E. Wechsler, MD, MMSc
Director, Asthma Program
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine                                            
National Jewish Health
Denver, CO

Dr. Wechsler is Professor of Medicine and Director of the Asthma Program in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health in Denver. He is board certified in both Pulmonary and Critical Care Medicine. Dr. Wechsler's research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome, CSS). He has published more than 100 peer-reviewed manuscripts relating to asthma, CSS and eosinophilic lung diseases.


Dr. Wechsler is a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicenter asthma clinical trials consortium. He has served as Principal Investigator of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ACRN LARGE trial, Partners Genetics Enters Medicine Initiative-funded GABLE trial and the AHRQ funded Blacks and Exacerbations on LABA or Tiotropium (BELT) trial. He is currently serving as Principal Investigator of an NHLBI sponsored study of asthma therapies in African Americans that examines race-specific differences in response to asthma therapy. He is also leading an NIAID sponsored study exploring anti IL5 in CSS.


A member of the American Society of Clinical Investigation, Dr. Wechsler has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. Professor Wechsler also serves as Associate Editor of the Journal Allergy and is on the editorial Board of the European Journal of Clinical Investigation. Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. 

Monica Kraft, MD

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair of Medicine
University of Arizona
Tucson, AZ

Prior to joining the University of Arizona in 2014, Dr. Monica Kraft, MD, was at Duke University, where she served as chief of the Division of Pulmonary, Allergy and Critical Care, as the Charles C. Johnson, MD, Distinguished Professor of Medicine, and as director of the Duke Asthma, Allergy and Airway Center. As vice chair for research in the Duke University Department of Medicine from 2009-2013, Dr. Kraft implemented several important initiatives to support the department's research endeavors and was instrumental in the re-submission and renewal of Duke's National Institutes of Health-funded Clinical Translational Science Award (CTSA). Prior to joining Duke in 2004, Dr. Kraft served as director of the Carl and Hazel Felt Laboratory in Adult Asthma Research and as medical director of the pulmonology physiology unit at the National Jewish Medical and Research Center in Denver, CO.

1. Identify and address remediable causes of poor asthma control.
2. Review the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with Type 2 inflammation and those in late-stage development.
3. Incorporate agents targeted at Type 2 inflammation into the management of appropriate patients with severe, uncontrolled asthma not responding to ICS and bronchodilator therapy.

CONTINUING EDUCATION CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians. 

Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The American Academy of PAs and the American Association of Nurse Practitioners accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit.™ from organizations accredited by the ACCME.

DISCLOSURES 
Dr. Kraft discloses the following:
Grants/Research Support: Chiesi USA, Sanofi
Consultant: AstraZeneca, Regeneron, Sanofi, Teva

Dr. Wechsler discloses the following:
Grants/Research Support: AstraZeneca, Novartis, Sanofi, Teva
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Teva
 
Dr. DiMango discloses that her spouse is employed by Regeneron.

The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
 
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
 
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses. 

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

COMMERCIAL SUPPORT
This activity is supported by an educational grant from AstraZeneca.
 

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above